VIVUS (NASDAQ:VVUS), the pharma company that just started selling its new obesity drug Qsymia, may not be angling for a buyout; but it sounds like one of its shareholders, QVT Financial, thinks this is the best possible strategy.

In the following video, health-care analysts Max Macaluso and David Williamson discuss this news, and whether a buyout makes sense for the under-fire drugmaker.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.